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Pharmacological inhibition of the MAPK pathway with
MEK or BRAF antagonists has proved successful in
inducing regression of melanoma tumors bearing the
targeted activating mutations. Moreover, antibodies
targeting T-cell immune checkpoint inhibitors CTLA-4
or PD-L1/PD-1 have demonstrated the capacity to gen-
erate durable responses in patients with multiple cancer
types. Thus, combining MAPK pathway-targeted agents
with antibodies that enhance anti-tumor immunity
represents an increasingly attractive treatment paradigm
for cancer. However, little is known about the impact of
tumor-targeted agents on immune function as similar
signaling pathways drive both T-cell activation and can-
cer cell proliferation. Accordingly, agents targeting
MAPK-dependent tumor growth would be predicted to
also inhibit T-cell immunity. Here we show that, unex-
pectedly, potent suppression of T-cell receptor (TCR)
function by MEK inhibition can be largely overcome in
the presence of co-stimulation by anti-CD28 in vitro or
blockade of the inhibitory PD-L1/PD-1 pathway in
T cells in vivo. The ability of anti-CD28 to override
suppression of T-cell activation by MEK inhibitors was
dependent on the PI3K/mTOR pathway. Enhanced
anti-tumor activity was also observed combining MEK
inhibition with PD-L1 blockade, which was likely poten-
tiated by upregulation of tumor MHC Class I expression
through inhibition of MEK. Interestingly, inhibitors
targeting BRAF V600E mutations actually augmented
TCR-driven proliferation in vitro and T-cell function in
vivo when combined with a vaccine or blockade of
PD-L1 exclusively in the context of a wildtype BRAF
background. These data demonstrate that targeting the
MAPK pathway can be compatible with or even
enhance T-cell function and provide rationale for
combining these inhibitors with immunotherapy in
clinical trials.
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